12:00 AM
Jul 21, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

QPI-1007: Phase IIa started

SBI Biotech’s Quark Pharmaceuticals Inc. subsidiary began a double-blind, sham-controlled, international Phase IIa trial to evaluate single intravitreal injections of 1.5 mg QPI-1007 in about 60 patients with unilateral acute primary angle-closure glaucoma.

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >